[Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia]

Area of Science:

• Urology
• Oncology
• Diagnostic Medicine

Background:

• Prostate specific antigen (PSA) is a biomarker used in prostate cancer screening.
• Distinguishing between benign prostatic hyperplasia (BPH) and prostate cancer can be challenging.
• Elevated PSA levels can occur in both BPH and prostate cancer.

Purpose of the Study:

• To evaluate the diagnostic utility of PSA in differentiating prostate cancer from BPH.
• To establish recommendations for biopsy in patients with BPH and elevated PSA levels.

Main Methods:

• Retrospective analysis of 163 patients diagnosed with prostatic hyperplasia.
• Assessment of prostate specific antigen (PSA) levels in relation to diagnosis.

Main Results:

• Prostate specific antigen (PSA) is not a cancer-specific marker.
• A PSA level greater than 4 ng/ml in patients with prostatic hyperplasia is indicative of potential prostate cancer.

Conclusions:

• Biopsy is recommended for patients with prostatic hyperplasia and PSA > 4 ng/ml to facilitate early diagnosis of prostate cancer.
• Current methods to increase PSA specificity for differentiating BPH are not completely reliable.